J. Robert

发表

Predicting drug response based on gene expression.

Jacques Robert, Jacques Bonnet, J. Robert, 2004, Critical reviews in oncology/hematology.

Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy

P. Perego, J. Robert, 2015, Cancer Chemotherapy and Pharmacology.

ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

H. Lenz, S. Im, Q. Wei, 2011, Clinical Cancer Research.

Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.

J. Robert, J. Bonnet, Delphine Meynard, 2007, Oncology reports.

Multidrug resistance reversal agents.

J. Robert, C. Jarry, 2003, Journal of medicinal chemistry.

Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.

V. Brouste, S. Mathoulin-Pélissier, I. Soubeyran, 2007, Pharmacogenomics.

Long-term and short-term models for studying anthracycline cardiotoxicity and protectors

J. Robert, 2007, Cardiovascular Toxicology.

Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.

J. Robert, S. Pond, L. Rivory, 1996, Biochemical pharmacology.

[Gene polymorphisms].

J. Robert, 2010, Bulletin du cancer.

Integrative analysis of genomic and transcriptomic alterations of AGR2 and AGR3 in cancer

E. Chevet, J. Robert, F. Delom, 2022, bioRxiv.

Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes.

J. Robert, M. Varache-Lembège, S. Moreau, 2008, European journal of medicinal chemistry.

Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.

P. Vrignaud, L. Mauriac, J. Robert, 1985, Cancer treatment reports.

Age dependence of the early-phase pharmacokinetics of doxorubicin.

J. Robert, B. Hoerni, 1983, Cancer research.

No association between XRCC 3 Thr 241 Met and XPD Lys 751 Gln polymorphisms and the risk of colorectal cancer in West Algerian population : a case – control study

S. Médiène-Benchekor, J. Robert, Lotfi Louhibi, 2014 .

Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.

J. Robert, M. Ratinaud, M. Verdier, 2006, Biochemical pharmacology.

Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients

M. Ychou, M. D. Rio, J. Robert, 2016, Clinical Pharmacokinetics.

Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.

J. Robert, L. Rivory, P. Canal, 1994, Cancer research.

Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.

J. Robert, S. Pond, J. Riou, 1996, Cancer research.

The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms

J. Robert, L. Rivory, C. Riché, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.

J. Armand, J. Robert, L. Rivory, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.

J. Robert, J. Riou, H. Dodds, 1998, The Journal of pharmacology and experimental therapeutics.

Variability in the pharmacokinetics of epirubicin: a population analysis

D. Kerr, J. Robert, J. Wade, 2004, Cancer Chemotherapy and Pharmacology.

Limited sampling models for doxorubicin pharmacokinetics.

M. Ratain, J. Robert, W. van der Vijgh, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Tyrosine kinase inhibitors].

J. Robert, 2011, Bulletin du cancer.

Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.

J. Robert, A. Laroche-Clary, Z. Jóźwiak, 2014, Toxicology in vitro : an international journal published in association with BIBRA.

Assessment of the experimental model of transplanted C6 glioblastoma in wistar rats

P. Vrignaud, J. Robert, J. Coindre, 1989, Journal of Neuro-Oncology.

Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture.

P. Couvreur, J. Robert, S. Bennis, 1994, European journal of cancer.

Doxorubicin encapsulation in liposomes and nanospheres for the reversal of multidrug resistance in vitro: 87

J. Robert, Y. Hu, S. Bennis, 1994 .

[Intracellular accumulation of free doxorubicin and doxorubicin encapsulated in nanospheres].

J. Robert, E. Bogush, I. Shubina, 1994, Biulleten' eksperimental'noi biologii i meditsiny.

Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.

I. Soubeyran, J. Robert, A. Laroche-Clary, 2004, Anticancer research.

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN‐38

J. Robert, M. Longy, Delphine Meynard, 2004, Clinical pharmacology and therapeutics.

Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines

J. Robert, D. Montaudon, V. Charasson, 2002, Cancer Chemotherapy and Pharmacology.

Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

J. Jougon, J. Robert, H. Bégueret, 2011, Molecular Diagnosis & Therapy.

Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

J. Robert, L. Rivory, 2004, Cancer Chemotherapy and Pharmacology.

Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.

J. Robert, L. Rivory, Jacques Robert, 1995, Pharmacology & therapeutics.

First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.

J. Robert, E. Brain, P. Schöffski, 2017, European journal of cancer.

A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.

I. Soubeyran, A. Italiano, H. Bonnefoi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Platinum Drugs and DNA Repair: Lessons from the NCI Panel and Clinical Correlates

J. Robert, Delphine Meynard, A. Laurand, 2009 .

Patients Lung Derived Tumoroids (PLDTs) to model therapeutic response.

J. Robert, H. Bégueret, A. Khatib, 2020, Biochimica et biophysica acta. Molecular cell research.

Multicentric evaluation of the MDR phenotype in leukemia

J. Rossi, F. Pinguet, B. Drénou, 1997, Leukemia.

Clinical impact of extensive molecular profiling in advanced cancer patients

I. Soubeyran, Y. Laizet, M. Toulmonde, 2017, Journal of Hematology & Oncology.

Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model.

D. Platel, J. Robert, S. Bonoron-Adèle, 1999, Anti-cancer drugs.

The P‐Glycoprotein 170: Just a Multidrug Resistance Protein or a Protean Molecule?

J. Robert, M. Ratinaud, M. Verdier, 2009 .

A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours

D. Frappaz, G. Vassal, J. Robert, 2006, British Journal of Cancer.

P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.

J. Robert, B. Schott, S. Huet, 1992, British Journal of Cancer.

Short curcumin treatment modulates oxidative stress, arginase activity, aberrant crypt foci, and TGF-β1 and HES-1 transcripts in 1,2-dimethylhydrazine-colon carcinogenesis in mice.

J. Robert, A. Laroche-Clary, V. Le Morvan, 2012, Toxicology.

Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture.

P. Vrignaud, J. Robert, D. Londos-Gagliardi, 1986, Oncology.

CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics

Chris Sander, Augustin Luna, Mirit I. Aladjem, 2020, Nucleic Acids Res..

Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy

Jacques Robert, Gilles Vassal, G. Vassal, 2008, Pathology & Oncology Research.

A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients

P. Hérait, A. Monnier, J. Robert, 2004, Cancer Chemotherapy and Pharmacology.

Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines

J. Robert, 2004, Cancer Chemotherapy and Pharmacology.

Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma.

J. Robert, L. Rivory, J. Robert, 1994, Journal of chromatography. B, Biomedical applications.

Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes

J. Robert, C. Riché, D. Ratanasavanh, 2002, Cancer Chemotherapy and Pharmacology.

Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin.

P. Vrignaud, J. Robert, B. Schott, 1990, British Journal of Cancer.

Fatty Acid Composition Transport and Metabolism in Doxorubicin-sensitive and-resistant Rat Glioblastoma Cells 1

P. Vrignaud, J. Robert, D. Montaudon, 2006 .

Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.

D. Platel, J. Robert, L. Tariosse, 2006, Toxicology letters.

Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention

J. Robert, L. Tariosse, S. Bonoron-Adèle, 1996, British journal of pharmacology.

Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome.

J. Robert, R. Bellott, P. Pouna, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation

J. Robert, A. Laroche-Clary, Z. Jóźwiak, 2015, Cellular Oncology.

Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug

J. Robert, C. Granger, M. David, 2004, Cancer Chemotherapy and Pharmacology.

Clinical Pharmacokinetics of Epirubicin

J. Robert, 1994, Clinical pharmacokinetics.

Epirubicin. Clinical pharmacology and dose-effect relationship.

J. Robert, 1993, Drugs.

Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma.

J. Robert, N. B. Bui, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Human pharmacokinetics of N‐l‐leucyl‐doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities

J. Robert, M. Marty, D. Belpomme, 1992, Clinical pharmacology and therapeutics.

Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.

A. Guillouzo, J. Robert, M. L. Le Bot, 1988, Biochemical pharmacology.

Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.

J. Reiffers, J. Robert, P. Hurteloup, 1987, Leukemia research.

Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.

P. Vrignaud, J. Robert, A. Iliadis, 1985, European journal of cancer & clinical oncology.

Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines

J. Robert, M. Ratinaud, M. Verdier, 2001, Anti-cancer drugs.

Determination of drug interactions occurring with the metabolic pathways of irinotecan.

J. Robert, M. Haaz, V. Charasson, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes.

J. Robert, L. Rivory, D. Ratanasavanh, 1997, Pharmacology & toxicology.

Pharmacokinetics and metabolism of anthracyclines.

J. Robert, L. Gianni, 1993, Cancer surveys.

Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.

G. Milano, J. Robert, P. Canal, 1994, British Journal of Cancer.

Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.

J. Robert, P. Pourquier, S. Lumbroso, 2015, Pharmacogenomics.

Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.

J. Robert, B. Schott, Jacques Robert, 1989, Biochemical pharmacology.

Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.

D. Platel, J. Robert, S. Bonoron-Adèle, 2000, Toxicology and applied pharmacology.

Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration?

J. Robert, 1987, Cancer drug delivery.

Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity.

J. Robert, P. Pourquier, A. Laroche-Clary, 2012, Carcinogenesis.

Tentative dose-monitoring of doxorubicin in lymphoma patients

P. Vrignaud, J. Robert, T. Nguyen-Ngoc, 1985, Medical oncology and tumor pharmacotherapy.

Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin

D. Platel, J. Robert, S. Bonoron-Adèle, 1999, British Journal of Cancer.

Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.

J. Robert, A. Laroche-Clary, A. Larrue, 2000, Biochemical pharmacology.

Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death.

J. Robert, S. Huet, D. Montaudon, 1998, Biochemical pharmacology.

Protein arginine (N)‐methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins

J. Markovits, F. Ichas, J. Robert, 2008, FEBS letters.

Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms.

J. Robert, E. Lippert, A. Bidet, 2014, European journal of cancer.

MS-209 Schering.

J. Robert, 2004, Current opinion in investigational drugs.

Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations.

J. Robert, S. Chevillard, O. Legrand, 1997, Seminars in hematology.

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer

J. Robert, N. Dohollou, F. Dalenc, 2020, Clinical pharmacology and therapeutics.

Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia

A. Baruchel, G. Leverger, T. Leblanc, 2001, Cancer Chemotherapy and Pharmacology.

Metabolism of methoxymorpholino‐doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes

J. Robert, Christopher Menard, D. Ratanasavanh, 2001, Fundamental & clinical pharmacology.

Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.

J. Robert, L. Rivory, M C Haaz, 1998, Cancer research.

Candidate biomarker assessment for pharmacological response

G. Mills, W. Reinhold, Y. Pommier, 2020, Translational oncology.

Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies.

J. Robert, Y. P. Hu, 1995, Biochemical pharmacology.

Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin.

J. Robert, B. Schott, M. Benchekroun, 1993, European journal of biochemistry.

Semisynthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11)

J. Robert, L. Rivory, M. Vuilhorgne, 1996 .

Induction of apoptosis by doxorubicin-transferrin conjugate compared to free doxorubicin in the human leukemia cell lines.

J. Robert, A. Laroche-Clary, Z. Jóźwiak, 2014, Chemico-biological interactions.

Pharmacological Properties of Oral Idarubicin

J. Robert, 1995 .

Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.

J. Armand, J. Robert, P. Hurteloup, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.

J. Robert, D. Montaudon, P. Pourquier, 1994, Anticancer research.

Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance

S. Clarke, J. Robert, H. Dodds, 2000, Cancer Chemotherapy and Pharmacology.

Phospholipid acyl group composition in normal and tumoral nerve cells in culture

J. Robert, J. Louis, D. Montaudon, 1981, Lipids.

Pharmacology of irinotecan.

J. Robert, L. Rivory, Jacques Robert, 1998, Drugs of today.

Extraction of Anthracyclines from Biological Fluids for HPLC Evaluation

J. Robert, 1980 .

Predicting drug response and toxicity based on gene polymorphisms.

J. Robert, P. Pourquier, J. Bonnet, 2005, Critical reviews in oncology/hematology.

Drug resistance in oncology: from concepts to applications

J. Robert, A. Demaille, J. Cazin, 2005, Journal of Cancer Research and Clinical Oncology.

Drug resistance to topoisomerase II inhibitors.

J. Robert, A. Larsen, 1998, Biochimie.

No association between XRCC3 Thr241Met and XPD Lys751Gln polymorphisms and the risk of colorectal cancer in West Algerian population: a case–control study

S. Médiène-Benchekor, J. Robert, Lotfi Louhibi, 2014, Medical Oncology.

A chemotherapy-associated senescence bystander effect in breast cancer cells

L. Elmore, S. Holt, D. Gewirtz, 2008, Cancer biology & therapy.

Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin

J. Robert, L. Tariosse, S. Bonoron-Adèle, 2004, Cancer Chemotherapy and Pharmacology.

Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients

B. Bui, J. Coindre, C. Bonaïti‐pellié, 2006, International journal of cancer.

Resistance to cytotoxic agents.

J. Robert, 2001, Current opinion in pharmacology.

Clinical Pharmacokinetics of Idarubicin

J. Robert, 1993, Clinical pharmacokinetics.

Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.

M. Ychou, N. Vié, P. Martineau, 2017, European journal of cancer.

Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.

J. Robert, S. Huet, C. Chapey, 1993, European journal of cancer.

On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance

P. Couvreur, J. Robert, C. Dubernet, 1996, Cancer Chemotherapy and Pharmacology.

Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation.

J. Robert, C. Chapey, Y. P. Hu, 1996, Cancer letters.

Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line

F. Ichas, J. Robert, Sanae Bennis, 1995, International journal of cancer.

Multidrug resistance in oncology: diagnostic and therapeutic approaches

J. Robert, 1999, European journal of clinical investigation.

Approaches to multidrug resistance reversal.

J. Robert, 1998, Expert opinion on investigational drugs.

Resistance to anticancer drugs: are we ready to use biologic information for the treatment of patients with cancer?

J. Robert, 1998, Therapeutic drug monitoring.

Major improvement of the reference method of the French drug resistance network for P-glycoprotein detection in human haematological malignancies.

J. Robert, A. Laurand, S. Huet, 2005, Leukemia research.

Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance

J. Robert, Y. Hu, Yan Hu, 2005, Journal of Cancer Research and Clinical Oncology.

Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.

J. Robert, L. Rivory, M C Haaz, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Gene Expression Signature Predicting High-Grade Prostate Cancer Responses to Oxaliplatin

A. Kauffmann, J. Robert, P. Pourquier, 2012, Molecular Pharmacology.

Catecholamine histofluorescence in the median eminence of female rabbits activated by mating

J. Robert, C. Bensch, J. Faure, 2005, Journal of Neural Transmission.

Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.

J. Robert, B. Schott, 1989, Biochemical pharmacology.

Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene

J. Robert, J. Bonnet, U. Zanger, 2008, Cancer Chemotherapy and Pharmacology.

Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma

J. Robert, E. Richard, D. Fessart, 2020, British Journal of Cancer.

Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma

S. Mathoulin-Pélissier, J. Robert, E. Richard, 2020, British Journal of Cancer.

Free fatty acid uptake is increased in doxorubicin-resistant glioblastoma cells

J. Robert, Patricia Vrignaud, 1987 .

Fluorescence anisotropy of cell membranes of doxorubicin-sensitive and -resistant rodent tumoral cells.

P. Vrignaud, J. Robert, D. Montaudon, 1986, Cancer research.

7β-Hydroxycholesterol-induced energy stress leads to sequential opposing signaling responses and to death of C6 glioblastoma cells.

J. Robert, E. Uro-Coste, M. Mersel, 2012, Biochemical pharmacology.

Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.

P. Lagarde, J. Robert, D. Montaudon, 1997, European journal of biochemistry.

Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells.

J. Robert, N. Henry-Toulmé, Y. P. Hu, 1995, European journal of cancer.

The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models

J. Kanno, J. Toutain, J. Robert, 2009, British Journal of Cancer.

Evaluation of antiproliferative and anti-inflammatory activities of methanol extract and its fractions from the Mediterranean sponge

J. Robert, A. Laroche-Clary, A. Bouraoui, 2012, Cancer Cell International.

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

J. Blay, B. Bui, J. Coindre, 2011, Cancer.

Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models

J. Robert, T. Yamori, A. Laroche-Clary, 2010, Molecular Cancer Therapeutics.

Preclinical Development Cytochrome P 450 1 B 1 Gene Polymorphisms as Predictors of Anticancer Drug Activity : Studies with In vitro Models

J. Robert, T. Yamori, A. Laroche-Clary, 2010 .

[Biology of cancer metastasis].

J. Robert, 2013, Bulletin du cancer.

Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial

S. Litière, H. Bonnefoi, D. Cameron, 2014, The Pharmacogenomics Journal.

Pharmacokinetics of doxorubicin in sarcoma patients

P. Vrignaud, J. Robert, N. B. Bui, 2004, European Journal of Clinical Pharmacology.

Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines

J. Robert, B. Schott, S. Huet, 2005, Journal of Cancer Research and Clinical Oncology.

Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls

J. Robert, J. Robert, 2006, Cell Biology and Toxicology.

Quantification of the expression of multidrug resistance-related genes in human tumour cell lines grown with free doxorubicin or doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres.

J. Robert, J. Bonnet, E. Soma, 2004, Anticancer research.

Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells.

J. Robert, M. Ratinaud, F. Grandjean, 2002, Biochemical pharmacology.

Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines.

J. Robert, S. Bennis, C. García, 1993, Biochemical Pharmacology.

Sanfilippo A syndrome (Mucopolysaccharidosis III A): a neurochemical study

G. Guazzi, A. Federico, J. Robert, 1981, The Italian Journal of Neurological Sciences.

Early-phase pharmacokinetics of doxorubicin in non-hodgkin lymphoma patients

P. Vrignaud, J. Robert, B. Hoerni, 1983, Cancer Chemotherapy and Pharmacology.

Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines

J. Robert, G. Smirnova, I. Shubina, 2004, Cancer Chemotherapy and Pharmacology.

Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network.

J. Robert, N. Gualde, S. Huet, 1998, Cytometry.

Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin

J. Robert, S. Bennis, C. Chapey, 1997, Anti-cancer drugs.

French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours

F. Pinguet, P. Validire, J. Kouyoumdjian, 1997, Leukemia.

Inhibition of Topoisomerase I Cleavage Activity by Thiol-reactive Compounds

M. Bjornsti, J. Robert, P. Pourquier, 2007, Journal of Biological Chemistry.

Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients.

J. Robert, C. Chevreau, R. Bugat, 1989, European journal of cancer & clinical oncology.

Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.

J. Robert, P. Hurteloup, F. Rigal‐Huguet, 1990, Leukemia.

Transcriptional down‐regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin‐resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine

J. Robert, A. Clary, Annick Larrue, 1998, Anti-cancer drugs.

Fatty Acid Composition and Metabolism of Tumor Cells Rendered Resistant to the Anticancer Drug Doxorubicin

P. Vrignaud, J. Robert, D. Montaudon, 1986 .

Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.

A. Kauffmann, J. Robert, A. Laroche-Clary, 2012, Pharmacogenomics.

Fatty acid composition transport and metabolism in doxorubicin-sensitive and-resistant rat glioblastoma cells.

P. Vrignaud, J. Robert, D. Montaudon, 1986, Cancer research.

A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients

R. Bouabdallah, C. Rose, P. Fenaux, 1999, Leukemia.

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

J. Robert, P. Hurteloup, F. Rigal‐Huguet, 1992, Hematological oncology.

Doxorubicin‐induced oxygen free radical formation in sensitive and doxorubicin‐resistant variants of rat glioblastoma cell lines

J. Robert, M. Benchekroun, B. Sinha, 1993, FEBS letters.

Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver

P. Vrignaud, J. Robert, R. Poupon, 2004, Cancer Chemotherapy and Pharmacology.

Hepatic metabolism of doxorubicin in mice and rats

P. Vrignaud, J. Robert, D. Londos-Gagliardi, 1985, European Journal of Drug Metabolism and Pharmacokinetics.

Differential over‐expression of mdr1 genes in multidrug‐resistant rat glioblastoma cell lines selected with doxorubicin or vincristine

J. Robert, P. Pourquier, B. Schott, 1993, International journal of cancer.

Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model.

F. Pinguet, J. Robert, I. Solassol, 2009, European journal of cancer.

Anterior Gradient-2 (AGR2) is overexpressed in colon cancer and is a potential biomarker of microsatellite instability (MSI) tumors

V. Brouste, I. Soubeyran, I. Mahouche, 2022, bioRxiv.

Anterior Gradient-2 (AGR2) overexpression in colon cancer: a potential prognostic biomarker

V. Brouste, I. Soubeyran, I. Mahouche, 2021 .

The Anterior GRadient (AGR) family proteins in epithelial ovarian cancer

J. Robert, F. Delom, D. Fessart, 2021, Journal of experimental & clinical cancer research : CR.

Extracellular AGR2 triggers lung tumour cell proliferation through repression of p21CIP1.

D. Bernard, J. Robert, E. Richard, 2020, Biochimica et biophysica acta. Molecular cell research.

Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line

J. Robert, P. Pourquier, C. Massart, 1995, Anti-Cancer Drugs.

On the use of pharmacogenetics in cancer treatment and clinical trials.

E. Giovannetti, G. Peters, J. Robert, 2014, European journal of cancer.

Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.

J. Robert, S. Huet, J. Chauvergne, 1988, European journal of cancer & clinical oncology.

Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance

J. Robert, C. Riché, M. Berlion, 2004, Cancer Chemotherapy and Pharmacology.

Comparison of 12 multidrug-resistance modulating agents in a model of doxorubicin-resistant rat glioblastoma cells in vitro

J. Robert, S. Huet, S. Bennis, 1994 .

Molecular Determinants of the Cytotoxicity of Platinum Compounds

Jacques Robert, Jacques Bonnet, J. Robert, 2004, Cancer Research.

Abstract 2200: Relationship between cytochrome P450 1B1 (CYP1B1) and head and neck cancer cells proliferation, dissemination and chemosensitivity to anticancer drugs.

J. Robert, A. Lansiaux, V. Morvan, 2013 .

Abstract 1872: Identification of novel single-nucleotide polymorphisms associated with anticancer drug effects using the SNPChip384 platform

J. Robert, A. Laroche-Clary, C. Hubert, 2012 .

Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel.

S. Mathoulin-Pélissier, J. Robert, J. Bonnet, 2006, Pharmacogenomics.

Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel.

J. Robert, V. Le Morvan, N. Nief, 2007, European journal of cancer.

FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

S. Mathoulin-Pélissier, Y. Bécouarn, J. Robert, 2014, BMC Research Notes.

FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

S. Mathoulin-Pélissier, Y. Bécouarn, J. Robert, 2014, BMC Research Notes.

Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver.

J. Robert, M. Haaz, C. Farabos, 2001, Journal of pharmaceutical sciences.

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study

J. Robert, F. Dalenc, W. Jacot, 2019, Clinical pharmacology and therapeutics.

[Multicentric evaluation of MDR phenotype in leukemia: intermediate analysis of the French study].

J. Robert, A. Faussat, R. Zittoun, 1996, Bulletin du Cancer.

Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture.

P. Vrignaud, J. Robert, F. Ballet, 1986, Pharmacological research communications.

[Pharmacology of camptothecin and its derivatives].

J. Robert, L. Rivory, 1995, Bulletin du cancer.

Measurement of doxorubicin-induced lipid peroxidation under the conditions that determine cytotoxicity in cultured tumor cells.

J. Robert, M. Benchekroun, 1992, Analytical biochemistry.

Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation

J. Robert, A. Laroche-Clary, Z. Jóźwiak, 2015, Cellular Oncology.

[Organic food consumption and cancer risk: A high-quality study and inappropriate reactions].

J. Robert, 2018, Bulletin du cancer.

Abstract 1871: Role of CYP1B1 gene polymorphisms in anticancer drug cytotoxicity as studied on isogenic cell lines

J. Robert, E. Richard, A. Lansiaux, 2012 .

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.

J. Robert, N. Ifrah, E. Gamelin, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.

J. Robert, E. Gamelin, M. Boisdron-Celle, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.

J. Robert, A. Cailleux, E. Gamelin, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Results of a phase I study of DTS-201, a peptidic prodrug of doxorubicin, in patients with solid tumors

J. Robert, S. Faivre, E. Brain, 2007 .

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer

J. Coindre, G. MacGrogan, S. Mathoulin-Pélissier, 2003, British Journal of Cancer.

Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines

J. Robert, M. Longy, V. Le Morvan, 2006, British Journal of Cancer.

[New concepts for the study of anticancer drug resistance].

J. Robert, 2002, Bulletin du Cancer.

A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients

P. Hérait, A. Monnier, J. Robert, 2004, Cancer Chemotherapy and Pharmacology.

Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture

M. Crouzet, J. Robert, P. Pourquier, 1996, Anti-cancer drugs.

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

J. Blay, B. Bui, J. Coindre, 2011, Cancer.

Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells

J. Robert, R. Baurain, G. Aubel-Sadron, 2004, Cancer Chemotherapy and Pharmacology.

[A study of the expression of MDR1 gene in solid tumors. Initial results of a multicenter evaluation].

J. Robert, S. Chevillard, P. Vielh, 1996, Bulletin du cancer.